Sara Ahlström
COO and Deputy CEO
Replay available
Apotea (Stockholm:APOTEA) Q1 2025 earnings call, held 2025-05-08. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/apotea-ab-apotea-q1-2025-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Good morning everyone and welcome to the presentation of Apothea's first quarter report. We are presenting here today from our office in Stockholm. We will start with a quite short presentation and the business update and then we will move on to a Q&A with spoken questions. Today's presenters will be Per Svadsson, our CEO and co-founder, Johan Morild, our CFO, and myself, Sara Ahlström, COO and Deputy CEO. And we will start by highlighting some quarterly highlights.
0:34 Thank you. We have had a good quarter. We have had improved profitability and stable growth. Johan, let's look at the figures.
0:47 Yes, we had revenues of 1 billion 754 million in the quarter and a solid growth of 15.2%. We increased the EBIT margin from 4.1% Q1 2024 to 5.3% first quarter.
1:06 And if we look at the quarter, we can see increased market uncertainty. It's obvious for everyone in the world, but the market is a little bit unstable, but we live in a very stable part of the market. If we look back with the last 25 years, the pharmacy market has been growing every year. So in both good times and crisis. So it's stable and we had a solid growth. driven by underlying demand. And we have also increased our market shares and increased profitability. So actually, we're a little bit above our corridor now, but it's been sunny.
1:51 During the quarter, we also focused quite a lot on the preparations for the new fulfillment center in Varberg. We're happy to see that everything is still proceeding according to plan, and our plan is still to go live during this summer. We are currently finalizing or testing the automation I should say and starting to also recruit key personnel to the warehouse.
2:14 Yes and with the solid growth in the quarter we're now approaching 6.8 billion in rolling 12 months net revenues and rolling 12 months adjusted EBIT margin of 4.7%. We didn't have any items affecting comparability in the quarter. Last year we had non-recurring items of 24 million and those costs were related to the IPO in December. Let's look at the growth of the quarter. As mentioned we had growth of 15.2%. We had more or less equal growth in RX as well as in OTC and traded goods. Hence you can see that the product mix in the quarter is in line with what it was a year ago the growth was primarily driven by a solid and stable underlying market demand and also affected by the fact that easter took place after the end of the period to the right you can see our gross margin development we had a fairly stable gross margin slightly increase and the that increase is due to improved purchasing terms We were able to increase our profitability in Q1 compared to Q1 24.
3:33 EBIT increased from 62 million to 92 million and the margin uplift is the result of the increased gross margin and also continued tight cost control, cost management and an increased capacity utilization in line with what we've said before in language early communication we expect gradually our costs related to Varberg to increase as we start the production there this summer and ramp up the organization on site start depreciation the machinery in Varberg as we start production and also will have a lower capacity utilization initially To the right hand side you see our costs and depreciation in percentage of net revenue.
4:22 It's been going down year over year as you can see. Personnel cost in relation to sales decreased from 8.6% to 7.5% and that decrease was the result of increased efficiency and also that we are today using external staffing. to a larger extent than a year ago, meaning that we're shifting costs from personnel costs to other operating costs. We increased our operating cash flow from 78 million Q1 2024 to 123 million Q1 2025. The operating cash flow financed the investments in the period of 117 million.
5:10 and that investment was mainly related to our new fulfillment center in Varberg. And the increased operational cash flow was due to the increased profitability. To the right you see a breakdown of networking capital. Inventory turnover was 8.7 times and slightly increased than from a year ago. The net working capital will fluctuate over time and there will be variations from quarter to quarter. Finally, let's have a look on the balance sheet and some balance sheet ratios. To the left you can see our return on capital employed.
5:57 Return on capital employed was close to 34% and increased from a year ago due to the increased profitability. We maintain a solid balance sheet and a low net debt despite our investments in Varberg. As of end of Q1, we had a net debt to EBTA ratio of 0.2.
6:27 And if we look a little bit ahead, the focus ahead would be to continue to build the pharmacy of tomorrow. and improve the customer experience. And with the new warehouse in Varberg, we will absolutely do that because then we can deliver same day to the West Coast. But to continue to improve the customer offering is very, very important for us, but also to build efficiency, improve the efficiency and lower our costs. But we also live in an uncertain world. I mean, we have a big war going on in Europe. We have a trade war going on in the world and several other conflicts. So we focus quite a lot on our own security, especially cybersecurity.
7:19 But we also look into maybe increase the stock levels a little bit. So reduce the risk of shortfalls of products and look over the total organization so we are really prepared for uncertain times. But to work with all this and continue to increase the efficiency is very important.
7:48 And as we said in the beginning, we are doing the preparations for the Varberg Fulfillment Center. Everything is proceeding according to plan and once I think for this quarter as well or the coming months, our focus is of course the launch of the new Fulfillment Center and also the ramp up of the new Fulfillment Center. So once that is up and running, we will see an increased capacity of around 50%. So we'll go from approximately 100,000 orders a day to approximately 150,000 orders each day. and the go live is planned this summer. We're also very, very close to launching a new Rx hub in the south of Stockholm in Årsta. This is, of course, according to our plan to increase the Rx capacity.
8:33 We think also it's a good location to attract and recruit pharmacists living in the south of Stockholm. And finally, I think we should also mention perhaps technology. We have used technology since the start to optimize our business and also to to really have efficiency gains. And we have talked a lot for the past two presentations also about the AI and the new AI department. And I think we are super happy to see that a few new AI projects are also being launched. And we feel quite confident that this will also help us to also improve the optimization of the operations, but also the customer offering going forward. So good steps, I think.
9:20 That was also the last slide of this quite short presentation. We will now open up for a Q&A with spoken questions. So let's start. Question comes from Johan Fred from SEB. Please go ahead.
9:38 Yes. Good morning, guys. Thank you for taking my questions. a first one on the gross margin development could you elaborate on on sort of the drivers behind the the gross margin improvement you state that the the the improvements come as a result of of purchasing terms but i also note the decent growth in in in your service offering so potentially a bit of a mix there as well and also if you could elaborate on your private label selection and how that has impacted the gross margin that would be very helpful, thank you.
10:19 Yes, the gross margin is fairly stable but as you mentioned it's also slightly increased and it's due to our long-term efforts to increase the purchasing terms and the supplier and purchasing terms is a combination of course of the purchasing prices but also other contributions from our suppliers and that mix is an important, that is what's driving the increased gross margin somewhat.
10:52 And our own products have a much higher gross margin compared to other products so they will also help to increase and we have launched like 30 new products i think and we sell more and more of them so they will absolutely contribute to going forward but it's still a small share of the total revenues
11:21 And how much of your revenues was generated from your own brands during Q1?
11:26 I don't have that figure in front of me. As of Q4, we had 1% of the sales roughly related to own products. This is a long term objective for us to increase the own product sales, but it will be a long run.
11:49 Got it. Did you see a, without quoting any specific numbers, did you see a sequential growth from Q4?
11:59 We see a solid, we see a very good growth in our own product.
12:07 Okay. Thank you. And the second question on sort of your contingency preparation. You state that this may affect your inventory levels over the course of the year. How should we think about this in terms of networking capital? Are you planning to build up or stack up on inventory or how should we interpret the comment?
12:33 Yeah, I think we shall. And then we're not sure we're going to do that. But we might do that because if we see that it's a risk of logistics problem around the world, we might add some inventory But you might never notice it, because it might be just within a quarter or so. Or if you see bigger problems, we might add maybe 100 million Swedish to the stock or something like that. But we're not sure, because we read the newspapers, see what happens, and follow it very closely.
13:17 Okay, got it. Got it. Very clear. And the final one from me on sort of Rx sales and your hiring of pharmacists. Is there any way you could disclose how many pharmacists you currently have on staff?
13:34 I think we said the last time that our goal or ambition for the full year is approximately 200 pharmacists and I would say that we are steadily recruiting towards that that ambition. So I think we have a quite, we welcome a lot of new colleagues every week and we're super happy to see that we can attract pharmacists to our business. So a steady growth in the number.
13:56 The launch of the RX in Southern Stockholm is part of that effort to increase the capacity long term in RX.
14:04 Exactly.
14:07 Yeah, perfect. Very clear. Thank you so much for taking the time, guys. Those were all of my questions. Thank you. The next question comes from Frederick Iverson from ABG. Please go ahead.
14:22 Thank you. Good morning, guys. A few questions from me as well. Good morning. Can we come back to the gross margin and the improved purchasing prices that you mentioned? Do you expect a positive impact from this over the coming quarters as well, or is it more isolated to Q1?
14:45 Our goal is to have a stable gross margin so we are not like promising an increasing gross margin and it's going a little bit up and a little bit down so but I think you better that you calculate with a quite stable gross margin instead of increasing.
15:06 But on those improved purchasing prices just that sort of isolated impact do you expect that to be a continuous driver of the gross margin?
15:18 We will absolutely continue to negotiate with our suppliers and try to hide them but on the other side we have a growing RX and that an RX have a little bit lower gross margin so we can compensate with that so our goal is to have a stable
15:40 one. Yeah that's clear. Great. And then second question on the Easter impact. You mentioned it in the report and in the presentation. What's your assessment of the Easter impact in Q1?
15:55 We had Easter last year in Q1. This year it was in Q2. We tend to have a bit slower sales during this kind of vacation period. like a positive impact in Q1. It's hard to say a precise figure of the impact of that season effect.
16:19 You always have some seasonal impacts every year. I mean, you have like if it's a Monday or a Sunday, last day of the month. So it differs a little bit, but it has some impact, absolutely. Yeah.
16:37 Okay, fair. And last question from my side on the external staffing. You mentioned you're increasing that gradually, and I guess we can see this in a sort of gradual decrease of the number of employees that you've had during the last year or so. How should we think about this as we look ahead in a like-for-like basis?
17:08 I think if we look ahead, we will probably have approximately the same number of consultants compared to own staff in warehouse. So from now on, I think we will see a decrease in personnel, but that's more like the real figure. Now it's more like a mix of them.
17:38 Right. And when you look at the cost per employee in sort of like-for-like terms, how has that developed during the last 12 months?
17:48 It's approximately the same.
17:52 Approximately the same. Okay. Excellent. That's all my questions. Thank you.
17:56 Thank you. The next question comes from Victor Hansen from Carnegie. Please go ahead.
18:06 Yes, thank you. And hi, Per, Sara and Johan. A couple of questions from my side. Firstly, I noticed that other products bounced back up to 15% growth versus 9% in Q4. So did you do anything differently this time or what do you think drove this?
18:26 No, I think, I mean, if you look at the quarter, it's quite a short time and it goes a little bit up and down.
18:36 so it's not a big difference and I don't think it's next quarter it might be the opposite okay okay so on Warburg I was hoping you can give a bit of an update here on could you give an estimate of additional costs for Warburg coming in q2 and is your plan till still to start deliveries from July, meaning Q3.
19:07 I think the main, we will start ramping up the cost in connection to the start this summer. And so we will use the full impact of the costs in Q3 for sure. And what we can say and have said before is, I mean, you will start depreciation of the machinery in Barbary and that's an investment of 350 to 380 million. which will then depreciate over five years time starting from production launch this summer.
19:42 And if you look at the cost I mean now we have like five approximately five employees in Varberg and we maybe add that to 10-15 and during second quarter so I mean it's not a very big cost but we're absolutely adding up some costs. But during the third quarter, we will have much more costs, but then we also have revenue from that cost. So it's not big, but it's still costs coming up.
20:17 Yeah, but that's helpful in giving the magnitude of the number of employees, so that's helpful. And a final question from my side. If you could give an update on parallel import here in Q1 and also going forward. We have the stronger FIEC currently, so perhaps your parallel input could benefit from this.
20:42 Yes, I think we can say that we have really focused on this area for the fall and going forward. And I think we can anticipate an impact of it continuously. I wouldn't say quarter to quarter is a quite short period still, but we are focusing on this area and we will see that it will have an effect in the long term to do a good job in this area. But of course, this is one factor that affects, of course, but also the availability on the market and so on. So it's different factors and parameters that mix. Yeah.
21:24 Okay, thank you. The next question comes from Daniel Schmidt Schmidt from Danske. Please go ahead.
21:33 Yes, good morning, Per, and you want a couple of questions. from my side I think you mentioned that you were above the corridor that you've been guiding for when it comes to EBIT margin impressively so in the quarter and at the same time you're saying that you expect the gross margin to be stable going forward and you're also highlighting that you will take on higher depreciations from the summer when it comes to VARB and maybe a little bit more cost But given the growth that you're seeing, do you think that Q1 was an anomaly in terms of profitability and it will go back down on the back of these factors that I just mentioned when you look ahead?
22:17 I think the first quarter was a good quarter because we have said three to five and now we're a little bit above five. So we want to continue to guide you three to five. So is that an answer?
22:42 So you're basically saying that that will shave off what's coming up is going to shave off the outperformance versus your own corridor that you had in Q1 in the coming quarters. Is that the fair assumption?
22:55 Yeah, at least we don't want to guide you on something above five.
23:03 Okay, cool. Then on the macro, you continue to take share when you look at the entire market, but you've been trailing online growth, as I look at it, for now three quarters. What is the reason for that?
23:19 I think if you look at the total market, we are increasing our market share on the total market. On the e-commerce market, if you like the physical chains, if they move on volume from offline to online, or if they don't, I don't really care about that. For us, it's important that we grow and we grow our market share of the total market. So that's what we focus on.
23:55 Okay. Thank you so much. That's all for me.
23:58 Thank you. The next question comes from Ake Alm. Please unmute your microphone.
24:20 Hello, any questions from Åke?
24:24 I think you're still on mute if you want to try to unmute. No. We give you one second to unmute if you want to ask questions. Otherwise, that was it for today's session. Thank you very much for listening in. Our next quarterly report is released on the 18th of July, and we wish you all a pleasant day. Thank you for listening.
25:00 Thank you very much.
Follow Apotea AB into a list and get an email when it puts out news.
COO and Deputy CEO
CFO
Analyst, SEB
Analyst, Carnegie
Analyst, ABG
Analyst, Danske
CEO and Co-founder